1. Home
  2. ZLAB vs PFS Comparison

ZLAB vs PFS Comparison

Compare ZLAB & PFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ZLAB
  • PFS
  • Stock Information
  • Founded
  • ZLAB 2013
  • PFS 1839
  • Country
  • ZLAB China
  • PFS United States
  • Employees
  • ZLAB N/A
  • PFS N/A
  • Industry
  • ZLAB Biotechnology: Pharmaceutical Preparations
  • PFS Savings Institutions
  • Sector
  • ZLAB Health Care
  • PFS Finance
  • Exchange
  • ZLAB Nasdaq
  • PFS Nasdaq
  • Market Cap
  • ZLAB 3.4B
  • PFS 2.4B
  • IPO Year
  • ZLAB 2017
  • PFS N/A
  • Fundamental
  • Price
  • ZLAB $31.92
  • PFS $19.58
  • Analyst Decision
  • ZLAB Buy
  • PFS Strong Buy
  • Analyst Count
  • ZLAB 6
  • PFS 5
  • Target Price
  • ZLAB $57.22
  • PFS $23.00
  • AVG Volume (30 Days)
  • ZLAB 807.7K
  • PFS 469.7K
  • Earning Date
  • ZLAB 11-11-2025
  • PFS 10-28-2025
  • Dividend Yield
  • ZLAB N/A
  • PFS 4.89%
  • EPS Growth
  • ZLAB N/A
  • PFS 90.74
  • EPS
  • ZLAB N/A
  • PFS 1.77
  • Revenue
  • ZLAB $427,799,000.00
  • PFS $823,468,000.00
  • Revenue This Year
  • ZLAB $42.62
  • PFS $30.91
  • Revenue Next Year
  • ZLAB $55.12
  • PFS $10.36
  • P/E Ratio
  • ZLAB N/A
  • PFS $11.12
  • Revenue Growth
  • ZLAB 32.56
  • PFS 92.62
  • 52 Week Low
  • ZLAB $20.17
  • PFS $14.34
  • 52 Week High
  • ZLAB $44.34
  • PFS $22.24
  • Technical
  • Relative Strength Index (RSI)
  • ZLAB 46.25
  • PFS 53.05
  • Support Level
  • ZLAB $26.67
  • PFS $19.66
  • Resistance Level
  • ZLAB $33.06
  • PFS $20.05
  • Average True Range (ATR)
  • ZLAB 1.37
  • PFS 0.34
  • MACD
  • ZLAB 0.08
  • PFS -0.06
  • Stochastic Oscillator
  • ZLAB 66.14
  • PFS 12.50

About ZLAB Zai Lab Limited

Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.

About PFS Provident Financial Services Inc

Provident Financial Services Inc is the holding company for The Provident Bank, a community-oriented bank. The Company's operations are solely in the financial services industry and include providing traditional banking and other financial services to its customers. The Company operates in the geographical regions of northern and central New Jersey, Queens and Nassau Counties in New York and eastern Pennsylvania. The Company has a single reporting segment for financial reporting purposes. The majority of the revenue-generating activities that are components of non-interest income are These revenue streams can generally be classified into three broad categories: wealth management revenue, insurance agency income, and banking service charges and other fees.

Share on Social Networks: